Latest news with #Stada
Reuters
7 days ago
- Business
- Reuters
Stada in talks with two private equity groups over sale, Welt reports
BERLIN, June 3 (Reuters) - German pharmaceutical firm Stada is in talks with two private equity investors about a sale, Germany's Welt newspaper reported on Tuesday. Its owners Bain Capital and Cinven could seek an initial public offering in October if talks on a sale do not come to fruition, the report cited an unnamed source as saying.
Bloomberg
28-04-2025
- Business
- Bloomberg
German Drugmaker Stada Set to Refinance Debt After IPO Delay
Takeaways NEW German drugmaker Stada Arzneimittel AG is looking to refinance some of its junk debt, after pushing back a planned initial public offering intended to cut its liabilities. Stada launched the sale of notes worth €965 million on Monday, with the proceeds earmarked for refinancing the company's 7.5% senior secured bonds due 2026. The firm may also look to refinance some of its loans shortly, according to people familiar with the matter who asked not be identified because the talks are private.
Wall Street Journal
08-04-2025
- Business
- Wall Street Journal
Stada Postpones IPO Due to Market Volatility
Stada is postponing its initial public offering in Germany, the latest IPO candidate to put plans to go public on hold after U.S. President Trump's tariff blitz rattled markets globally. The German healthcare company said Tuesday that it is evaluating a new date for its IPO due to geopolitical uncertainties and market volatility.
Reuters
04-04-2025
- Business
- Reuters
Putin names little known firm to run pharma company spun off from Germany's Stada
MOSCOW, April 4 (Reuters) - Russia's president Vladimir Putin has appointed a little known company to manage assets linked to major German pharmaceutical firm Stada, according to a decree published on Friday. Since the start of the invasion of Ukraine and subsequent flight of many foreign businesses, Putin has issued several decrees to transfer foreign-owned assets to"temporary management", mostly by the state. The Reuters Tariff Watch newsletter is your daily guide to the latest global trade and tariff news. Sign up here. In late 2023, Stada spun off its Russian business into a separate company called Nizhpharm, which was to operate independently and autonomously. In its 2023 results presentation the company said it had exited Russia. Nizhpharm is ranked among the top 10 companies operating in Russia's $25 billion pharmaceutical market, which has escaped Western sanctions and is still dominated by international giants. Nizhpharm is owned by Luxembourg-based Nidda Lynx S.a r.l., defined in Stada's 2024 report as "a subsidiary of an indirect parent entity" of the group parent firm Nidda German Topco GmbH. The decree said that the temporary management will be carried out by a Russian pharmaceutical distribution company called Pharmirus. Temporary management has previously been introduced at Russian subsidiaries of a dozen foreign companies, including Danish brewer Carlsberg, Finnish utility Fortum ( opens new tab, German utility Uniper ( opens new tab and French yoghurt maker Danone ( opens new tab. Western companies and legal consultants have described it as a way for Russia to seize and redistribute assets. However, in a reverse decision, Italian water heating firm Ariston Holding ( opens new tab said on March 26 it had returned into possession of its Russian unit after Putin annulled last year's decision to seize it. Putin asked the government in March to outline procedures for Western companies to return to Russia. But he said there would be no easy road back for companies that had "slammed the door defiantly" when they pulled out of the country, and some would find that their niches had already been filled by Russian competitors. Stada postponed a planned initial public offering (IPO) earlier this year in Frankfurt, sources told Reuters, because of market volatility related to geopolitical situation. ($1 = 85.2455 roubles)
Yahoo
04-04-2025
- Business
- Yahoo
Putin seizes control of pharmaceutical giant with German roots
Russian ruler Vladimir Putin has placed Nizhpharm, one of Russia's largest pharmaceutical manufacturers, under temporary control. Source: Russian Telegram channel The Bell Details: The relevant decree applies to 100% of the shares held by the Luxembourg-based company Nidda Lynx S.A.R.L., part of the German group Stada. The new temporary administrator of the assets is the Russian company Pharmirus. Founded in 2020, Pharmirus specialises in the supply of medicines. In 2022, the company reported losses, with revenue of around RUB 92 million (US$1million). Nizhpharm is one of Russia's oldest drug manufacturers, established in 1919. Stada acquired a controlling stake in the company in 2004. Following the beginning of the full-scale war, the ownership structure changed, and control passed to Stada's Luxembourg subsidiary. DSM Group's data indicates that in 2024 Nizhpharm ranked second in Russia for pharmacy sales in roubles (3.7% of the market) and third in terms of packaging volume (3.8%). The company's annual revenue grew by 11.2% to reach RUB 59.8 billion (US$650 million). Its portfolio includes more than 100 brands, such as Edarbi, Ermital, Artra, Ibuprofen, Diclofenac and Vitrum vitamins. Background: Despite official statements claiming a high number of companies from "unfriendly" countries want to return to Russia, not a single one has applied to resume operations on the Russian market. Support Ukrainska Pravda on Patreon!
